Paroxetine: current status in psychiatry

@article{Pae2007ParoxetineCS,
  title={Paroxetine: current status in psychiatry},
  author={C. Pae and A. Patkar},
  journal={Expert Review of Neurotherapeutics},
  year={2007},
  volume={7},
  pages={107 - 120}
}
  • C. Pae, A. Patkar
  • Published 2007
  • Medicine
  • Expert Review of Neurotherapeutics
    • Paroxetine is a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. It is commercially available in both an immediate-release (paroxetine) and a controlled-release formulation (paroxetine CR). The latter product was developed to improve gastrointestinal tolerability. Paroxetine is the most potent inhibitor of the reuptake of serotonin among the available SSRIs. It has approved indications for the treatment of major depression, obsessive–compulsive… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov
    39 Citations
    Background Citations
    20
    Methods Citations
    1
    Results Citations
    1
    39 Citations
    Citation Type

    Citation Type

    Paroxetine: safety and tolerability issues
    • 31
    Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder
    • 9
    A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
    • 113
    Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors
    • 47
    • PDF
    CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.
    • 28
    Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.
    • 74
    • PDF
    Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial.
    • 86
    • PDF
    Effect of comedication of bupropion and other antidepressants on body mass index
    • 5
    Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting
    • 21
    Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms.
    • 10

    References

    SHOWING 1-10 OF 109 REFERENCES
    Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    • 133
    Paroxetine: an update of its use in psychiatric disorders in adults.
    • 109
    Paroxetine Controlled Release
    • 26
    Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    • 107
    Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.
    • 113
    Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
    • 100
    Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics
    • 161
    Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression.
    • 167
    Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders.
    • W. Heydorn
    • Medicine
    • Expert opinion on investigational drugs
    • 1999
    • 22
    Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    • 57